UBS reiterates its 'neutral' stance on Sartorius Stedim Biotech, with a price target reduced from €276 to €232. This new target implies a potential upside of 11% for the stock of the French supplier of products and services to the pharmaceutical industry.

After a first-quarter publication deemed disappointing, the broker expects 'investors to remain cautious until there are consistent signs of recovery and a clear path towards targets for the 2024 financial year'.

Copyright (c) 2024 All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.